ZMS-2195 / Simcere - LARVOL DELTA

A novel highly potent multiple-RAS inhibitor ZMS-2195 efficiently blocks MAPK pathway activation and induces robust anti-tumor growth effects in preclinical models (AACR 2026) - "At a dose of 0.8 mg/kg, ZMS-2195 induced tumor regression in PK59 (KRASG12D/WT, PDAC) xenograft model. In summary, ZMS-2159 is a potent Multi-RAS inhibitor with robust activity against RAS-driven tumor cells, supporting its further development as a target therapy for cancers driven by diverse RAS aberrations."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BRAF • DUSP6 • HRAS • KRAS • NRAS